Pharma payments and free meals steer doctors toward pricier, less suitable drugs

A sweeping new Cochrane review has delivered one of the most comprehensive assessments to date of how pharmaceutical industry marketing shapes the way doctors prescribe medicines, and the findings are difficult to ignore. Drawing on evidence from more than 93 studies covering millions of prescribers across multiple health systems, an international research team that includes University of Toronto Associate Professor Quinn Grundy of the Lawrence Bloomberg Faculty of Nursing found that common promotional practices, from payments for consulting and advisory board membership to free meals and sales representative visits, are consistently associated with physicians prescribing more of the drugs a company is promoting. More troubling still, the review found a strong link between these marketing exposures and inappropriate prescribing, meaning clinicians were more likely to recommend treatments that patients may not need or that carry the potential for harm.

The review, published in the Cochrane Database of Systematic Reviews under the title Pharmaceutical industry information and promotional strategies aimed at prescribers, compiled observational data on prescribers who had received various forms of industry contact, including advertising and education, gifts and payments, and free samples. The technical strength of a Cochrane review lies in its systematic approach: the authors searched, appraised and synthesized studies according to predefined criteria, allowing patterns to emerge across heterogeneous settings rather than relying on any single investigation. What emerged was a coherent signal that exposure to industry promotion changes behavior in measurable ways, shifting prescribing toward promoted products and, in a substantial share of cases, away from prescribing that best serves patients clinically or economically.

Grundy, who also directs the WHO Collaborating Centre for Governance, Accountability, and Transparency in the Pharmaceutical Sector at the University of Toronto and is one of two Canadian authors on the review, emphasizes that these marketing tactics are not confined to any single country or regulatory environment. The same multi-national companies market their drugs worldwide, meaning the dynamics documented in the review likely apply broadly across health systems. In the United States, where the Open Payments system requires companies to publicly report transfers of value to physicians, just over half of all licensed physicians have accepted a payment of some kind, including something as ordinary as a free meal. That figure, Grundy notes, cuts two ways. It shows that companies concentrate their marketing resources on physicians expected to deliver the highest return on investment and to prescribe more of the promoted drug, but it also reveals that a large number of physicians deliberately choose not to interact with pharmaceutical companies at all and remain independent of these influences.

The economics of this influence deserve particular scrutiny. When physicians accept payments or meals, the data show they subsequently prescribe more of the promoted drug, and when that drug is a brand-name product with cost-effective alternatives available, the consequences ripple outward through the health system. Patients face higher co-pays and greater out-of-pocket costs, while payers and public programs absorb inflated drug expenditures that may deliver no additional clinical benefit. In this sense, the review frames industry promotion not merely as an ethical concern about professional independence but as a measurable driver of health system costs and of inequities in what patients pay at the pharmacy counter.

Canada occupies a revealing position in this evidence base. No Canadian studies were included in the review, largely because the country lacks a mechanism to track how much pharmaceutical companies pay physicians and nurse practitioners, or why those payments are made. Unlike the United States, which maintains its public Open Payments database, Canada has no comparable transparency infrastructure at the national level. Grundy points out that surveys and qualitative research outside this review suggest free meals and payments are nonetheless likely common among Canadian prescribers, meaning the absence of Canadian data reflects a gap in transparency rather than an absence of the phenomenon itself. For policymakers, this is a concrete and actionable finding: a country cannot manage or evaluate influences it does not measure.

The review did not stop at documenting the problem. A subset of the included studies examined what happens when institutions adopt conflict-of-interest policies or restrict physician interactions with industry within practice settings such as medical schools and teaching hospitals. The results were encouraging. In environments where such policies were in place, physicians tended to prescribe less overall, or to prescribe more appropriate treatments, suggesting that structural safeguards can meaningfully mitigate the effects of promotional exposure. The review authors argue that more robust conflict-of-interest policies represent an important way forward, shifting the burden of independence from the individual conscience of each clinician to the systems in which care is delivered.

Grundy frames this as a matter of institutional responsibility rather than personal blame. Prescribers, she argues, need independent, evidence-based sources of drug information to maintain their independence in practice and to remain trustworthy and accountable to the people they serve. The studies included in the review demonstrate that practice environments can be deliberately designed to promote and preserve that independence, and that this is best achieved collectively, within health systems and institutions, rather than leaving individual clinicians to resist sophisticated, well-resourced marketing campaigns on their own. This reframing matters, because decades of research on professional behavior suggest that relying solely on individual willpower against systematic commercial pressure is a weak intervention compared with changing the environment itself.

There is also an important scope question raised by the findings. While most of the available research focused on physicians, physicians are no longer the only prescribers in many health systems, including Canada. Descriptive studies using the United States Open Payments data, which were not part of this review, have found that advanced practice nurses, including nurse practitioners and clinical nurse specialists, are also targets of industry promotion. As scope-of-practice expansions place more prescribing authority in the hands of nurses and other non-physician clinicians, the reach of pharmaceutical marketing expands with it. Grundy is explicit on this point: this is not just a problem for medicine, it affects the entire healthcare team, and the goal should be to create healthcare environments that safeguard the independence and integrity of care for every prescriber within them.

For readers weighing the practical implications, the review offers a clear evidence-based agenda. Health professional schools, hospitals, professional societies and health systems can adopt and enforce conflict-of-interest policies that limit promotional contact, particularly during training when prescribing habits are formed. Jurisdictions without transparency mechanisms, Canada among them, can establish mandatory disclosure of industry payments to all prescribers, not only physicians. Clinicians and educators can prioritize independent sources of therapeutic information. And patients, whose co-pays and out-of-pocket costs absorb much of the financial consequence, have a stake in demanding that prescribing decisions rest on clinical evidence rather than commercial relationships. The Cochrane evidence indicates that none of these changes requires a scientific breakthrough, only the institutional will to act on what the data already show.

What makes this review resonate beyond academic circles is its scale and its consistency. With evidence from more than 93 studies and the observed practices of millions of prescribers, the association between industry payments and prescribing behavior is no longer a contested curiosity of health services research; it is a documented, repeatable pattern across health systems and regulatory regimes. The finding that conflict-of-interest policies measurably improve prescribing adds a constructive counterweight, demonstrating that the influence of promotion is neither inevitable nor irreversible. As Grundy and her colleagues make clear, the task now is to translate that evidence into policy, so that the environments in which clinicians train and practice actively protect the independence on which safe, appropriate and affordable prescribing depends.

Subject of Research: The influence of pharmaceutical industry marketing and payments on physician prescribing behavior

Article Title: Study links pharmaceutical industry payments to changes in physicians’ prescribing practices

Article References: Study links pharmaceutical industry payments to changes in physicians’ prescribing practices. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: pharmaceutical industry, prescribing practices, Cochrane review, conflict of interest, Open Payments, physician payments, drug marketing, health policy, inappropriate prescribing, healthcare costs, Quinn Grundy, University of Toronto